Health
COVID and cancer therapeutics: clinical trial and treatment disruption – European Pharmaceutical Review
EPR’s Hannah Balfour discusses how COVID-19 has impacted the pharma industry with regard to cancer clinical trial and treatment disruptions.
Posted: 19 February 2021 | Hannah Balfour (European Pharmaceutical Review) | No comments yet
In this article, European Pharmaceutical Reviews Hannah Balfour discusses how COVID-19 has impacted the pharma industry with regard to cancer clinical trial and treatment disruptions.
THE UNPRECEDENTED impact of COVID-19 has been far reaching, but the effects on cancer patients makes them one of the worst affected groups. Being immunocompromised, which is one of the most common effects associated with cancer…
Continue Reading
